Literature DB >> 6116722

Agonist-promoted high affinity state of the beta-adrenergic receptor in human neutrophils: modulation by corticosteroids.

A O Davies, R J Lefkowitz.   

Abstract

beta-Adrenergic agonists form high affinity complexes with receptors, resulting in activation of the associated adenylate cyclase. To examine the formation of the high affinity state of the receptor, curves were constructed for the competition of the full beta-adrenergic agonist isoproterenol, partial agonists cobefrin and soterenol, and the antagonist propranolol for [3H]dihydroalprenolol binding to beta-adrenergic receptors on human neutrophil membranes. Curve modeling by computer yielded a two-state binding model for the agonists, with distinct dissociation constants for the high (KH) and low (KL) affinity states. The ratio of dissociation constants (KL/KH) was found to be well correlated (P less than 0.01) with the drug's intrinsic activity for stimulation of adenylate cyclase. Thus, the degree of coupling of receptor occupation with adenylate cyclase activation is correlated with the magnitude of KL/KH. Administration of cortisone to humans resulted in a substantial rise in the proportion of receptors in the high affinity state and in the KL/KH determined from isoproterenol competition curves, as well as a rise in adenylate cyclase activity. Furthermore, in vitro exposure of human neutrophils to hydrocortisone resulted in a similar rise in KL/KH determined from isoproterenol competition curves. Therefore, one mechanism by which cortisone modulates beta-adrenergic receptor function appears to be through facilitating the formation of the high affinity state of the receptor, resulting in greater coupling of receptor occupation with adenylate cyclase activation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116722     DOI: 10.1210/jcem-53-4-703

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

Authors:  Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Impaired catecholaminergic signalling of B lymphocytes in patients with chronic rheumatic diseases.

Authors:  M Wahle; S Kölker; A Krause; G R Burmester; C G Baerwald
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 3.  Adrenal corticosteroids in the treatment of asthma.

Authors:  S C Siegel
Journal:  Clin Rev Allergy       Date:  1983-03

4.  In vitro desensitization of beta adrenergic receptors in human neutrophils. Attenuation by corticosteroids.

Authors:  A O Davies; R J Lefkowitz
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

Review 5.  The management of status asthmaticus in infants and children.

Authors:  G Kurland; A B Leong
Journal:  Clin Rev Allergy       Date:  1985-02

6.  Effects of methylprednisolone on hemodynamics and beta-adrenergic receptor signaling in rabbits with acute left ventricular failure.

Authors:  H Nishimura; T Yoshikawa; N Kobayashi; T Anzai; K Nagami; S Handa; S Ogawa
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

7.  Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo.

Authors:  J C Mak; M Nishikawa; H Shirasaki; K Miyayasu; P J Barnes
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 8.  Benefit-risk assessment of long-acting beta2-agonists in asthma.

Authors:  Catherine M Jackson; Brian Lipworth
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Paf-acether-induced death in mice: involvement of arachidonate metabolites and beta-adrenoceptors.

Authors:  M Criscuoli; A Subissi
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

10.  Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation.

Authors:  Kurt M Lucin; Virginia M Sanders; T Bucky Jones; William B Malarkey; Phillip G Popovich
Journal:  Exp Neurol       Date:  2007-06-02       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.